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reduced LVEF were mostly excluded. Furthermore,
baseline LVEF was significantly different in the sub-
groups. All of these factors might have influenced the
results.
In conclusion, the previous beneficial finding of
CTO PCI in CTO LAD patients was not supported in
serial CMR data. Therefore, the short-term results of
the EXPLORE trial do not support a strategy of
routine early CTO PCI in STEMI patients, regardless of
CTO location. However, the effect of CTO PCI in more
selected patients at a longer follow-up needs further
evaluation.
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Colorectal cancer is a potentially preventable disease,
as early lesions may be detected and removed during
screening colonoscopy. Emerging evidence suggests
associations between cardiovascular disease and
several cancers, including colorectal cancer. The
relationship is thought to arise from common risk
FIGURE 1 Recovery of LVEF and LVEDV in Total CMR Population and CTO LAD and CTO
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Delta (A) left ventricular ejection fraction (LVEF) and (B) left ventricular end-diastolic
volume (LVEDV) between baseline and 4-month follow-up in total cardiac magnetic
resonance imaging (CMR) population patients, chronic total occlusion (CTO) left anterior
descending artery (LAD) and CTO non-LAD patients. Change in LVEF and LVEDV was
compared between CTO percutaneous coronary intervention (PCI) (blue) and no-CTO
PCI (orange). Date are presented as means. Changes in LVEF and LVEDV were tested
with independent samples t test.
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factors including obesity, diabetes, hypertension,
smoking, unhealthy diet, and physical inactivity (1).
We studied potential associations of cardiovascular
risk (CVR), as assessed by the Framingham Risk Score
(FRS) (2) or the presence of coronary artery disease
(CAD), with colorectal neoplasia detected by
screening colonoscopy in a Caucasian cohort without
gastrointestinal symptoms.
The study was conducted in 2,098 participants of a
health-screening program according to national
screening recommendations for colorectal cancer
between 2010 and 2014. All consecutive patients
<79 years of age without gastrointestinal symptoms
that asked to be screened and agreed to participate in
the study were included. The study complies with the
Declaration of Helsinki and was approved by the local
ethics committee. Informed consent was obtained
from all participants.
Colonoscopic findings were classified as tubular
adenoma or advanced neoplasia (i.e., villous or
tubulovillous features), size $1 cm or high-grade
dysplasia, or carcinoma after analysis of macro-
scopic and histological results. Colonoscopic findings
were defined as outcome variables, while all other
variables as explanatory variables.
We used Statistica version 7.0 (StatSoft, Tulsa,
Oklahoma) or Stata version 13.0 (Stata Corporation,
College Station, Texas) statistical software. For com-
parison of categorical or continuous variables, we
used a contingency chi-square test or analysis of
variance, respectively. We estimated the odds ratio
(OR) with 95% confidence interval (CI) by univariate
logistic regression analysis. To provide separate ORs
for the middle and upper FRS tertiles and the group
with CAD history, we used 3 dummy variables with
the low tertile as reference.
Clinical characteristics of our study population
revealed associations of colonoscopic results with
several CVR factors (Table 1). Our population included
108 (5%) subjects with a self-reported history of CAD.
In 55 subjects, a previous coronary angiography
verifying CAD was available. In the remaining
53 subjects, CAD history was verified by review of
medical records. ORs for having any adenoma or
advanced neoplasia in subjects with CAD history were
1.51 (95% CI: 1.10 to 2.27; p ¼ 0.047) and 2.62 (95% CI:
1.31 to 5.20; p ¼ 0.007), compared with subjects
without CAD history, respectively.
Logistic regression models with FRS as predictor
variable in subjects without CAD revealed that a
1-percentage-point increase of FRS was associated
with ORs of 1.07 (95% CI: 1.06 to 1.09; p < 0.001) and
1.07 (95% CI: 1.04 to 1.12; p < 0.001) for the detection
of any and advanced neoplasia, respectively.
In comparison to the low-risk FRS tertile (refer-
ence), the intermediate-risk (OR: 1.95; 95% CI: 1.49 to
2.55) and the high-risk tertiles (OR: 3.35; 95% CI: 2.59
to 4.33) showed stepwise increases in ORs for any
colorectal adenoma (all p < 0.001) (Table 1). Addi-
tionally, for advanced neoplasia, a stepwise increase
in ORs was observed as well: low-risk tertile (refer-
ence), intermediate-risk tertile (OR: 1.66; 95% CI: 0.81
to 3.39; p ¼ 0.163), high-risk tertile (OR: 3.83; 95% CI:
2.04 to 7.19; p < 0.001), and CAD (OR: 5.47; 95% CI:
2.34 to 12.93; p < 0.001). Essentially, nearly identical
results were observed when applying the Heart Score
of the European Society of Cardiology (3) for the
estimation of CVR (data not shown).
Our study has some limitations. CAD was estab-
lished via questionnaire or medical history; however,
neither coronary angiography nor other screening
tests for CAD are justifiable in a population-based
TABLE 1 Characteristics of Subjects and Risk of Any Adenoma or Advanced









(n ¼ 85) p Value
Age, yrs 58.0  9.9 61.9  8.8 63.8  8.9 <0.001
Male 695 (45.3) 301 (62.8) 55 (64.7) <0.001
Smoking status 0.292
Never 737 (48.0) 233 (48.6) 47 (55.3)
Ever 558 (36.4) 170 (35.5) 21 (24.7)
Current 239 (15.6) 76 (15.9) 17 (20.0)
Arterial hypertension 942 (61.4) 317 (66.2) 53 (62.3) 0.170
Diabetes mellitus 199 (13.0) 81 (16.9) 17 (20.0) 0.028
FRS, % 6.9  6.1 9.5  6.5 10.8  6.6 <0.001
HSESC, %* 2.8  3.4 4.0  3.6 5.4  6.2 <0.001
History 0.010†
CAD 70 (4.6) 28 (5.8) 10 (11.8)
MI 20 (1.3) 9 (1.9) 2 (2.4)
Revascularization 36 (2.3) 18 (3.8) 7 (8.3)
Risk of Any Adenoma or Advanced Neoplasia by FRS Tertiles
CVR/CAD Groups‡ Screened Subjects Advanced Neoplasia
All subjects 2,098 85 (4.1)
Low FRS without CAD (0%–3%) 711 13 (1.8)
Intermediate FRS without CAD (4%–8%) 633 19 (3.0)
High FRS without CAD (>8%) 646 43 (6.7)
CAD 108 10 (9.6)
Values are mean  SD, n (%), or n. Subjects with and without colorectal adenoma and advanced
neoplasia differed significantly with respect to their (cardiovascular) characteristics. Risk of any
adenoma or advanced neoplasia by FRS (estimates the 10-year risk of a subject to develop coronary
heart disease) tertiles: number of screened subjects and the corresponding findings with respect to
any colorectal adenoma or advanced neoplasia in low, intermediate, and high FRS and CAD groups.
The p values refer to analysis of variance or contingency. Revascularization includes percutaneous
stents and/or coronary artery bypass graft. *Estimates the 10-year risk of a subject for cardio-
vascular death. †Value for CAD history, not significant for MI/revascularization. ‡FRS upper limits
of 3% and 8% for the low and intermediate risk groups were used, as other limits would have
resulted in even greater deviations from equality among tertiles. Thus, 711, 633, and 646 subjects
were assigned to the low, intermediate, and high tertiles. An additional analysis with an equal
distribution of colorectal neoplasms among risk groups revealed essentially the same results.
CAD ¼ coronary artery disease; FRS ¼ Framingham Risk Score; HSESC ¼ Heart Score of the
European Society of Cardiology; MI ¼ myocardial infarction.
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screening study. Furthermore, FRS does not include
diabetes, obesity, red meat or saturated fat intake, or
family history of colorectal cancer, all of which are
relevant for the assessment of colorectal cancer risk.
In conclusion, we report an association of CVR
factors and colorectal neoplasms. In this screening
cohort without gastrointestinal symptoms, subjects
with known CAD and high CVR had a significantly
higher probability of early and advanced colorectal
neoplasia compared with subjects with low CVR,
presumably due to shared risk factors. Our data sug-
gest screening colonoscopy to be indicated particu-
larly in subjects with known CAD or high CVR to
detect potentially treatable colorectal neoplasia.
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The Influence of Exercise
Therapy on the Heart
Failure Disease Pathway
We would like to thank Kosmala et al. (1) for their
recent publication, which expounded on the positive
relationship between spironolactone and exercise
tolerance in patients with heart failure (HF) with
preserved ejection fraction. Their work has already
garnered attention on the age-old adage of exercise
and its relationship with disease management in HF.
We would agree that exercise therapy could be a
means of achieving quality of life endpoints as
opposed to merely prolonging survival. Perhaps
monitoring exercise tolerance along with standard
biomarkers may reveal not only the progression of HF
in individual patients, but also the effectiveness of
exercise therapy over time.
As the management of HF is being relegated to the
outpatient setting, it becomes increasingly clear that
self-care is paramount in reducing readmissions and
decreasing mortality rates in this population.
Exercise therapy directly diminishes the levels of in-
flammatory biomarkers, such as tumor necrosis
factor-alpha and interleukin, in the voluntary mus-
cles of patients with HF (2). Because exercise
augments cerebral perfusion (3) and directly coun-
teracts the inflammatory response, exercise may be a
cost-effective therapy in HF (4). If patients with HF
were motivated to maximize self-care, a positive
feedback loop could potentially arise where exercise
improves executive function and affect to facilitate
adherence to therapy and medication regimens.
Of course, it is not always that easy. In the United
States alone, HF-associated costs will likely double
from $31 billion to $70 billion from 2012 to 2030 (5). To
add insult to injury, the aging population will in all
probability increase the prevalence of and morbidity
associated with HF management (5). HF has also been
identified as a scourge on the international scale,
discriminating not among nations of disparate re-
sources. The onus of HF will in all likelihood continue
to rise and is therefore a worldwide health concern
that international bodies such as the World Health
Organization are attempting to address (5).
This begs the question: Can the defeat of such a
pernicious nemesis truly be carried out by exercise,
which can be performed in one’s own backyard? It is
easy to say “yes.” The true answer, however, lies in
the will to act.
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